Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 2,503 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CAO Michael P. Dube sold 2,503 shares of Intellia Therapeutics stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $9.95, for a total value of $24,904.85. Following the completion of the sale, the chief accounting officer directly owned 57,137 shares in the company, valued at $568,513.15. This represents a 4.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Intellia Therapeutics Stock Performance

NTLA traded down $0.02 during trading hours on Thursday, reaching $10.72. The company's stock had a trading volume of 2,811,328 shares, compared to its average volume of 2,963,793. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18. The company's 50-day moving average is $8.68 and its 200-day moving average is $9.42. The firm has a market cap of $1.11 billion, a PE ratio of -2.05 and a beta of 2.21.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter last year, the company earned ($1.12) earnings per share. The firm's quarterly revenue was down 42.6% compared to the same quarter last year. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NTLA. Ensign Peak Advisors Inc boosted its position in shares of Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock worth $457,000 after acquiring an additional 1,100 shares in the last quarter. HighTower Advisors LLC lifted its stake in Intellia Therapeutics by 8.2% during the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock worth $120,000 after purchasing an additional 1,282 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock valued at $327,000 after purchasing an additional 1,615 shares in the last quarter. E Fund Management Co. Ltd. increased its stake in shares of Intellia Therapeutics by 10.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock valued at $210,000 after purchasing an additional 1,634 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Intellia Therapeutics by 56.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after buying an additional 1,655 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NTLA. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 16th. Canaccord Genuity Group lowered their price objective on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a report on Tuesday, June 3rd. Citigroup reduced their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Guggenheim decreased their target price on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Finally, Wedbush reissued a "neutral" rating and set a $7.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $33.37.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.